Computational Methods in Road towards Drug Discovery against SARS-CoV2

Syed Babar Jamal; Shumaila Naz; Raees Khan; Adnan Haider; Rabail Zehra Raza; Sumra Wajid Abbasi

doi:10.37185/LnS.1.1.166

Syed Babar Jamal National University of Medical Sciences, Rawalpindi
Shumaila Naz National University of Medical Sciences, Rawalpindi
Raees Khan National University of Medical Sciences, Rawalpindi
Adnan Haider National University of Medical Sciences, Rawalpindi
Rabail Zehra Raza National University of Medical Sciences, Rawalpindi
Sumra Wajid Abbasi National University of Medical Sciences, Rawalpindi

DOI: https://doi.org/10.37185/LnS.1.1.166

Keywords: SARS-CoV-2, COVID-19, In Silico Drug Design, Drug Repurposing

Abstract

SARS-CoV2 has affected millions of people around the globe with hundreds of mortalities. The emergence of SARS-COV2 is very recent, and there is no potential drug or vaccine available. In this review, we have compiled the most frequently used computational methods in drug discovery, target proteins of SARS-CoV2 as well as implementation of computational methods. Most recent literature on SARS-CoV2 has been compiled from various journal search engines including Google Scholar, Academia, PubMed, Scopus, Research Gate, and the Web of Science. The keywords chosen for the searches were COVID-19, Corona Virus, SARS-CoV2, drug development and future directions. This review has far reaching implications to both the public health and pharmaceutical industries for potential novel drug development against SARS-CoV2.

References

Roser M, Ritchie H, Ortiz-Ospina E, Hasell J. Coronavirus pandemic (COVID-19). Our World in Data. 2020.

Parr J. Pneumonia in China: lack of information raises concerns among Hong Kong health workers. 2020.

TanW,ZhaoX,MaX,WangW,NiuP,XuW,etal.Anovel coronavirus genome identified in a cluster of pneumonia cases—Wuhan, China 2019− 2020. China CDC Weekly. 2020; 2: 61-2.

Wang LS, Wang YR, Ye DW, Liu QQ. A review of the 2019 Novel Coronavirus (COVID-19) based on current evidence. International journal of antimicrobial agents. 2020; 19: 105948.

Veerareddy PR. Diverse Strategies in Drug Discovery and Development. EC Pharm. Toxicol. 2018; 6: 601-3.

Marshall SF, Burghaus R, Cosson V, Cheung SY, Chenel M, DellaPasqua O, et al. Good practices in model-informed drug discovery and development: practice, application, and documentation. CPT: pharmacometrics & systems pharmacology. 2016; 5: 93-122.

Wang T, Wu MB, Zhang RH, Chen ZJ, Hua C, Lin JP, et al. Advances in computational structure-based drug design and application in drug discovery. Current Topics in Medicinal Chemistry. 2016; 16: 901-16.

Basith S, Cui M, Macalino SJ, Choi S. Expediting the design, discovery and development of anticancer drugs using computational approaches. Current medicinal chemistry. 2017; 24: 4753-78.

Prajapat M, Sarma P, Shekhar N, Avti P, Sinha S, Kaur H, et al. Drug targets for corona virus: A systematic review. Indian journal of pharmacology. 2020; 52: 56- 65.

Wang H, Xue S, Yang H, Chen C. Recent progress in the discovery of inhibitors targeting coronavirus proteases. VirologicaSinica. 2016; 31: 24-30.

Satarker S, Nampoothiri M. Structural Proteins in Severe Acute Respiratory Syndrome Coronavirus-2. Archives of Medical Research. 2020.

Gallagher TM, Buchmeier MJ. Coronavirus spike proteins in viralentry and pathogenesis. Virology. 2001; 279: 371-4.

Kumar S. Drug and vaccine design against Novel Coronavirus (2019-nCoV) spike protein through Computational approach. Preprints (www. preprints. org) [Internet]. 2020.

Gralinski LE, Menachery VD. Return of the Coronavirus: 2019-nCoV. Viruses. 2020 ; 12: 135.

Chan JF, Kok KH, Zhu Z, Chu H, To KK, Yuan S, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerging microbes & infections. 2020; 9: 221-36.

Ruch TR, Machamer CE. The hydrophobic domain of infectious bronchitis virus E protein alters the host secretory pathway and is important for release of infectious virus. Journal of virology. 2011; 85: 675-85.

Liu DX, Yuan Q, Liao Y. Coronavirus envelope protein: a small membrane protein with multiple functions. Cellular and Molecular Life Sciences. 2007; 64: 2043-8.

Fung TS, Liu DX. Post-translational modifications of coronavirus proteins: roles and function. Future Virology. 2018; 13: 405-30.

Castaño-Rodriguez C, Honrubia JM, Gutiérrez-Álvarez J, DeDiego ML, Nieto-Torres JL, Jimenez-Guardeño JM, et al. Role of severe acute respiratory syndrome coronavirus viroporins E, 3a, and 8a in replication and pathogenesis. MBio. 2018; 9: e02325-17.

J Alsaadi EA, Jones IM. Membrane binding proteins of coronaviruses. Future Virology. 2019; 14: 275-86.

Neuman BW, Kiss G, Kunding AH, Bhella D, Baksh MF, Connelly S, et al. A structural analysis of M protein in coronavirus assembly and morphology. Journal of structural biology. 2011; 174: 11-22.

Gralinski LE, Menachery VD. Return of the Coronavirus: 2019-nCoV. Viruses. 2020; 12: 135.

McBride R, Van Zyl M, Fielding BC. The coronavirus nucleocapsid is a multifunctional protein. Viruses. 2014; 6: 2991-3018.

Chan JF, Kok KH, Zhu Z, Chu H, To KK, Yuan S, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerging microbes & infections. 2020; 9: 221-36.

V'kovski P, Gerber M, Kelly J, Pfaender S, Ebert N, Lagache SB, et al. Determination of host proteins composing the microenvironment of coronavirus replicase complexes by proximity-labeling. Elife. 2019; 8: e42037.

Zhang L, Lin D, Sun X, Curth U, Drosten C, Sauerhering L, et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors. Science. 2020; 368: 409-12.

Gao Y, Yan L, Huang Y, Liu F, Zhao Y, Cao L, et al. Structure of the RNA-dependent RNA polymerase from COVID-19 virus. Science. 2020; 368: 779-82.

Kim Y, Jedrzejczak R, Maltseva NI, Wilamowski M, Endres M, Godzik A, et al. Crystal structure of Nsp15 endoribonuclease NendoU from SARS-CoV-2. Protein Science. 2020.

Dong S, Sun J, Mao Z, Wang L, Lu YL, Li J. A guideline for homology modeling of the proteins from newly discovered betacoronavirus, 2019 novel coronavirus (2019-nCoV). Journal of medical virology. 2020.

Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, et al. A novel angiotensin-converting enzyme–related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circulation research. 2000; 87: e1-9.

ImaiY,KubaK,RaoS,HuanY,GuoF,GuanB,etal. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005; 436: 112-6.

Bhuvaneshwari S, Sankaranarayanan K. Identification of potential CRAC channel inhibitors: Pharmacophore mapping, 3D-QSAR modelling, and molecular docking approach. SAR and QSAR in Environmental Research. 2019; 30: 81-108.

Levoin N, Calmels T, Krief S, Danvy D, Berrebi-Bertrand I, Lecomte JM, et al. Homology model versus X-ray structure in receptor-based drug design: A retrospective analysis with the dopamine D3 receptor. ACS Medicinal Chemistry Letters. 2011; 2: 293-7.

Jacobson KA, Costanzi S. New insights for drug design from the X-ray crystallographic structures of G-protein-coupled receptors. Molecular pharmacology. 2012 ; 82: 361-71.

He G, Gong B, Li J, Song Y, Li S, Lu X. An improved receptor- based pharmacophore generation algorithm guided by atomic chemical characteristics and hybridization types. Frontiers in pharmacology. 2018; 9: 1463.

Yang H, Du Bois DR, Ziller JW, Nowick JS. X-ray crystallographic structure of a teixobactin analogue reveals key interactions of the teixobactin pharmacophore. Chemical Communications. 2017; 53: 2772-5.

Yang SY. Pharmacophore modeling and applications in drug discovery: challenges and recent advances. Drug discovery today. 2010; 15: 444-50.

Kist R, Timmers LF, Caceres RA. Searching for potential mTOR inhibitors: Ligand-based drug design, docking and molecular dynamics studies of rapamycin binding site. Journal of Molecular Graphics and Modelling. 2018; 80: 251-63.

Tropsha A. Best practices for QSAR model development, validation, and exploitation. Molecular informatics. 2010; 29: 476-88.

Vucicevic J, Nikolic K, Mitchell JB. Rational drug design of antineoplastic agents using 3D-QSAR, cheminformatic, and virtual screening approaches. Current medicinal chemistry. 2019; 26: 3874-89.

Lin X, Li X, Lin X. A review on applications of computational methods in drug screening and design. Molecules. 2020; 25: 1375.

Ferreira LG, Dos Santos RN, Oliva G, Andricopulo AD. Molecular docking and structure-based drug design strategies. Molecules. 2015; 20: 13384-421.

Seidel T, Bryant SD, Ibis G, Poli G, Langer T. 3D pharmacophore modeling techniques in computer-aided molecular design using LigandScout. Tutorials Chemoinform. 2017 ; 281: 279-309.

Ehrlich P. Über den jetzigen Stand der Chemotherapie. Berichte der deutschenchemischenGesellschaft. 1909; 42: 17-47.

Gund P. Three-dimensional pharmacophoric pattern searching. InProgress in molecular and subcellular biology. Springer, Berlin, Heidelberg. 1977; pp: 117-43.

Jin Z, Du X, Xu Y, De ng Y, Liu M, Zhao Y,et al. Structure of M pro from SARS-CoV-2 and discovery of its inhibitors. Nature. 2020; 9: 1-5.

Wu C, Liu Y, Yang Y, Zhang P, Zhong W, Wang Y, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharmaceutica Sinica B. 2020.

Wang J. Fast identification of possible drug treatment of coronavirus disease-19 (COVID-19) through computational drug repurposing study. Journal of Chemical Information and Modeling. 2020.

Mothay D, Ramesh KV. Binding site analysis of potential protease inhibitors of COVID-19 using Auto Dock. Virus Disease. 2020; 31: 194–99.

Shah B, Modi P, Sagar SR. In silico studies on therapeutic agents for COVID-19: Drug repurposing approach. Life Sciences. 2020; 252: 117652.

Wahedi HM, Ahmad S, Abbasi SW. Stilbene-based natural compounds as promising drug candidates against COVID- 19. Journal of Biomolecular Structure and Dynamics. 2020; 7: 1-0.

Amin SA, Ghosh K, Gayen S, Jha T. Chemical-informatics approach to COVID-19 drug discovery: Monte Carlo based QSAR, virtual screening and molecular docking study of some in-house molecules as papain-like protease (PLpro) inhibitors. Journal of Biomolecular Structure and Dynamics. 2020; 18: 1-0.